Baseline characteristics of patients with immune-mediated diseases
| Variable | Overall n=2 26 555 | AS n=8691 | IBD n=1 00 336 | PsA n=18 345 | RA n=99 183 |
| Age at diagnosis, median (range) | 50 (19–65) | 47 (19–65) | 47 (19–65) | 50 (19–65) | 53 (19–65) |
| Female, % | 62.8 | 45.9 | 54.7 | 53.4 | 74.2 |
| Comorbidities at or before diagnosis of immune-related diseases, % | |||||
| Diabetes mellitus | 10.8 | 8.9 | 8.0 | 12.3 | 13.5 |
| Hypertension | 33.1 | 30.9 | 26.2 | 35.5 | 39.9 |
| Dyslipidaemia | 33.1 | 31.3 | 26.5 | 36.0 | 39.4 |
| Medications within 84 days of index date, % | |||||
| Corticosteroids | 8.9 | 3.0 | 5.4 | 5.6 | 13.5 |
| Methotrexate | 9.2 | 2.0 | 0.1 | 17.5 | 17.4 |
| Other hepatotoxic medications* | 2.2 | 2.6 | 1.7 | 3.0 | 2.5 |
| Other biologics† | 1.1 | 0.2 | 0.1 | 2.9 | 1.8 |
| Follow-up in years since diagnosis, median (range) | 1.5 (0.0–6.0) | 1.3 (0.0–6.0) | 1.7 (0.0–6.0) | 1.3 (0.0–6.0) | 1.4 (0.0–6.0) |
*Other hepatotoxic medications include azathioprine, leflunomide and/or sulfasalazine.
†Other biologics include abatacept, ixekinumab, rituximab, secukinumab, and/or tocilizumab.
AS, ankylosing spondylitis; IBD, inflammatory bowel disease; PsA, psoriatic arthritis; RA, rheumatoid arthritis.